STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 89 filers reported holding STOKE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 2.22 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $43,080 | -73.3% | 10,934 | -28.0% | 0.00% | – |
| Q2 2023 | $161,492 | +501.9% | 15,192 | +371.7% | 0.00% | – |
| Q1 2023 | $26,831 | -53.8% | 3,221 | -48.9% | 0.00% | – |
| Q4 2022 | $58,131 | -28.2% | 6,298 | 0.0% | 0.00% | – |
| Q3 2022 | $81,000 | +17.4% | 6,298 | +20.1% | 0.00% | – |
| Q2 2022 | $69,000 | -37.8% | 5,242 | -0.7% | 0.00% | – |
| Q1 2022 | $111,000 | -12.6% | 5,281 | 0.0% | 0.00% | – |
| Q4 2021 | $127,000 | -5.2% | 5,281 | +0.6% | 0.00% | – |
| Q3 2021 | $134,000 | +45.7% | 5,252 | +93.1% | 0.00% | – |
| Q2 2021 | $92,000 | +17.9% | 2,720 | +35.7% | 0.00% | – |
| Q1 2021 | $78,000 | -29.1% | 2,005 | +12.3% | 0.00% | – |
| Q4 2020 | $110,000 | +39.2% | 1,785 | -23.7% | 0.00% | – |
| Q3 2020 | $79,000 | +61.2% | 2,340 | +13.6% | 0.00% | – |
| Q2 2020 | $49,000 | -18.3% | 2,059 | -21.4% | 0.00% | – |
| Q1 2020 | $60,000 | +17.6% | 2,618 | +45.3% | 0.00% | – |
| Q4 2019 | $51,000 | +59.4% | 1,802 | +20.9% | 0.00% | – |
| Q3 2019 | $32,000 | – | 1,490 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 296,822 | $7,551,000 | 1.86% |
| RTW INVESTMENTS, LP | 3,644,248 | $92,710,000 | 1.40% |
| Cormorant Asset Management, LP | 1,278,276 | $32,519,000 | 1.32% |
| Redmile Group, LLC | 2,381,958 | $60,597,000 | 1.06% |
| HighVista Strategies LLC | 47,594 | $1,211,000 | 0.80% |
| Birchview Capital, LP | 15,000 | $382,000 | 0.26% |
| GILDER GAGNON HOWE & CO LLC | 1,123,355 | $28,578,000 | 0.15% |
| Artal Group S.A. | 250,000 | $6,360,000 | 0.14% |
| Tekla Capital Management LLC | 99,263 | $2,525,000 | 0.08% |
| Casdin Capital, LLC | 120,000 | $3,053,000 | 0.08% |